# US 2023/0414763 A1 · Transmucosal amphiphile-protein conjugate vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414763 A1
- Document ID: US20230414763A1
- Status: Published application
- Kind: A1
- Application number: 18/117,752
- Filed: 2023-03-06
- Published: 2023-12-28
- Earliest claimed: 2022-03-04
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Darrell J. Irvine; Brittany L. Hartwell
- Web page: https://patentgrep.com/patent/US20230414763A1

## CPC

- A61K 47/544: {Phospholipids}
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 2039/543: {intranasal}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/575: {humoral response}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/6031: {Proteins}
- A61K 2039/627: {characterised by the linker}
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

What is disclosed is a vaccine comprising an immunogen conjugated to an albumin-binding polymer-lipid tail, wherein the vaccine is suitable for transmucosal (e.g, intranasal) administration. Also disclosed is a method of using the vaccine to immunize a subject by transmucosal (e.g, intranasal) administration of an effective amount of the vaccine, alone or with an adjuvant.

## Claims

### Claim 1

A vaccine comprising an amphiphilic conjugate, wherein the amphiphilic conjugate comprises an immunogen operably linked to an albumin-binding lipid, and wherein the vaccine is suitable for transmucosal administration to induce a humoral immune response.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the transmucosal administration is intranasal administration.

### Claim 3 (depends on 1)

The vaccine of claim 1, wherein the immunogen is a protein antigen having a molecular weight between about 10 kDa and about 500 kDa.

### Claim 4 (depends on 1)

The vaccine of claim 1, wherein the immunogen comprises a protein antigen selected from the group consisting of a human immunodeficiency virus (HIV) antigen, a SARS-CoV-2 antigen, an influenza antigen, a rotavirus antigen, a cytomegalovirus (CMV) antigen, an Epstein-Barr virus (EBV) antigen, a respiratory syncytial virus (RSV) antigen, and a cholera antigen.

### Claim 5 (depends on 1)

The vaccine of claim 1, wherein the immunogen comprises a monomer antigen or trimer antigen.

### Claim 6 (depends on 1)

The vaccine of claim 1, wherein the immunogen comprises an antigenic peptide.

### Claim 7 (depends on 1)

The vaccine of claim 1, wherein the albumin-binding lipid is selected from the group consisting of a cholesterol, a monoacyl lipid, and a diacyl lipid.

### Claim 8

(canceled)

### Claim 9 (depends on 6)

The vaccine of claim 6, wherein the albumin-binding lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE).

### Claim 10 (depends on 1)

The vaccine of claim 1, wherein the immunogen is operably linked to the albumin-binding lipid via a first linker.

### Claim 11 (depends on 10)

The vaccine of claim 10, wherein the first linker is selected from the group consisting of a hydrophilic polymer, a string of hydrophilic amino acids, polysaccharides, oligonucleotides, or a combination thereof.

### Claim 12 (depends on 11)

The vaccine of claim 11, wherein the first linker comprises a polyethylene glycol (PEG) linker.

### Claim at position 13

-14. (canceled)

### Claim 15 (depends on 10)

The vaccine of claim 10, further comprising a second linker, wherein the second linker is located between the immunogen and the first linker, or between the albumin-binding lipid and the first linker.

### Claim 16 (depends on 15)

The vaccine of claim 15, wherein the second linker comprises a PEG linker comprising repeating unit of PEG monomers.

### Claim 17 (depends on 16)

The vaccine of claim 16, wherein the second linker comprises 2 to 20 repeating units of PEG monomers, or 4 repeating units of PEG monomers.

### Claim 18

(canceled)

### Claim 19 (depends on 16)

The vaccine of claim 16, wherein the second linker comprises a dibenzocyclooctyne (DBCO) group covalently conjugated to the repeating unit of PEG monomers.

### Claim at position 19

-23. (canceled)

### Claim 24 (depends on 1)

The vaccine of claim 1, further comprising an adjuvant.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The vaccine of claim 1, wherein transmucosal administration of the vaccine elicits or enhances production of antibodies that bind to the immunogen.

### Claim at position 23

-28. (canceled)

### Claim 29 (depends on 1)

A method of vaccinating a subject, comprising transmucosally administering to the subject an effective amount of the vaccine of claim 1, thereby vaccinating the subject.

### Claim 30 (depends on 1)

A method of immunizing a subject, comprising transmucosally administering to the subject an effective amount of the vaccine of claim 1, thereby immunizing the subject.

### Claim 31 (depends on 29)

The method of claim 29, wherein the vaccine is administered intranasally to the subject.

### Claim at position 27

-34. (canceled)

### Claim 35 (depends on 29)

The method of claim 29, wherein the vaccine is administered at a dose of about 5 μg to about 300 μg, or at a dose of about 50 μg, 100 μg, or 150 μg.

### Claim 36

(canceled)

### Claim 37 (depends on 29)

The method of claim 29, wherein the vaccine is administered in combination with an adjuvant.

### Claim at position 31

-42. (canceled)
